Allogene Therapeutics Inc at Jefferies Healthcare Conference Transcript
Good afternoon. It's Michael Yee from the biotech team here at Jefferies. Really happy to have the CFO and what I would argue a legend in biotech, Eric Schmidt, certainly from a sell-side perspective.
Not yet from the CFO perspective is what you're saying.
Not yet from the CFO, but we're working on that. But certainly from the sell-side perspective, a legend to join me up here to talk about Allogene.
Eric, a lot going on. Obviously, we're just commenting that we just came back from ASCO. Obviously, you guys are starting a pivotal study. And maybe we could take a step back because I think that Wall Street has a lot of questions and concerns about CD19 CAR T, particularly from the allogeneic side and even the relapsed/refractory sort of second and third-line market as Yescarta moves upstream.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
